DiagnaMed Announces Dr. Bassma Ghali as Vice President of Product
March 22, 2023 07:30 ET
|
Diagnamed Holdings Corp.
TORONTO, March 22, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health AI company, is pleased to announce the addition of Dr. Bassma Ghali,...
DiagnaMed Announces Application for OTCQB Listing
March 09, 2023 07:30 ET
|
Diagnamed Holdings Corp.
Increasing awareness within the U.S. capital markets DiagnaMed focused on commercializing CERVAI™, its proprietary Brain Health AI Platform leveraging Generative AI TORONTO, March 09, 2023 (GLOBE...
DiagnaMed Enters into License Agreement with University of Miami for Brain Health Platform for Integration with CERVAI™, a Brain Health AI Platform Leveraging Generative AI
February 22, 2023 07:30 ET
|
Diagnamed Holdings Corp.
TORONTO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, is pleased to announce that it has entered...
DiagnaMed Prioritizes Development and Commercialization Initiatives for CERVAI™, a Brain Health AI Platform Leveraging Generative AI
February 14, 2023 07:30 ET
|
Diagnamed Holdings Corp.
TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, today announces that it is prioritizing...
DiagnaMed Announces Appointment of New Director
February 13, 2023 07:15 ET
|
Diagnamed Holdings Corp.
TORONTO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, announced today that Ms. Emily Davis resigned...
DiagnaMed Holdings Incorporates OpenAI’s ChatGPT into BRAIN AGE™ AI Product Suite
February 01, 2023 10:23 ET
|
Diagnamed Holdings Corp.
TORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), an artificial intelligence-driven digital health company focusing on improving brain...
DiagnaMed Holdings Provides Update for BRAIN AGE™ Development and Commercialization Milestones for 2023
January 31, 2023 08:00 ET
|
Diagnamed Holdings Corp.
Complete IRB-approved research study in Q2-2023 Commercialize BRAIN AGE™ in Q4-2023 TORONTO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE:...
DiagnaMed Holdings Acquires Exclusive Rights to a Virtual Reality and Artificial Intelligence-based Neurodiagnostic System for Neurodegenerative Disease
November 15, 2022 08:00 ET
|
Diagnamed Holdings Corp.
Exclusive license of intellectual property from the University of Kansas of a proprietary diagnostic tool combining artificial intelligence and virtual reality to assist in the diagnosis of...
DiagnaMed Holdings Announces Listing on the Canadian Securities Exchange
November 08, 2022 07:45 ET
|
Diagnamed Holdings Corp.
Focusing on novel AI-based digital diagnostics and therapeutics solutions for brain health Developing BRAIN AGE™, an electroencephalogram-based (EEG) artificial intelligence solution to detect an...